Sarpogrelate, a 5-HT2a receptor antagonist in intermittent claudication. A Phase II European study

Vascular Medicine

Volumn 11, Issue 2, 2006, Pages 75-83

  Norgren, Lars ^a   Jawien, A ^b   Matyas L ^c   Rieger, H ^d   Arita, K ^e  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c BAZM Korhaz es Rendelointezet Angiologiai Osztaly ^*  (Hungary)

^d Angiologische Abt der Aggertalklin   (Germany)

^e MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Intermittent claudication; MCI 9042; Sarpogrelate; Walking distance

Indexed keywords

ACETYLSALICYLIC ACID; DIURETIC AGENT; PLACEBO; SARPOGRELATE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SUCCINIC ACID DERIVATIVE;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; EUROPE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTERMITTENT CLAUDICATION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; TREADMILL EXERCISE; WALKING; DRUG ANTAGONISM; EXERCISE TEST; LEG; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; AGED; DOUBLE-BLIND METHOD; EUROPE; EXERCISE TEST; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; LOWER EXTREMITY; MALE; MIDDLE AGED; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; SUCCINATES; TREATMENT OUTCOME; WALKING;

EID: 33746530099     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x06vm657oa     Document Type: Article

References (28)

1. TransAtlantic Inter-Society Consensus (TASC) Working Group. Management of Peripheral Arterial Disease (PAD). J Vasc Surg 2000; 31: S1-296.
2. Taylor SM, Kalbaugh CA, Gray BH et al. The LEGS score: a proposed grading system to direct treatment of chronic lower extremity ischemia. Ann Surg 2003; 237: 812-18.
3. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000; 2: CD000990.
4. Clagett GP, Sobel M, Jackson MR, Lip GYH, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 609-26.
5. 2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004; 104: 59-81.
6. 2C receptor subtypes by molecular modeling. Life Sci 2003; 73: 193-207.
7. 2-serotonergic receptor antagonist. Thromb Haemost 1991; 65: 415-20.
8. Hara H, Osakabe M, Yamada K, Nako K, Tamao Y. Effect of sarpogrelate hydrochloride on contraction of blood vessels. Jpn Pharmacol Ther 1991; 19 (suppl 3): S611-18.
9. Hara H, Kitajima A, Tamao Y. Improvement of red blood cell deformability by a new anti-platelet agent, MCI-9042. Clin Hemorheol 1992; 12: 267-77.
10. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease. The European Agency for the Evaluation of Medicinal Products, 2002: CPMP/EWP/714/98 rev 1.
11. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifyllin for treating intermittent claudication. Am J Med 2000; 109: 523-30.
12. Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized multicenter trial. Arch Intern Med 1999; 159: 2041-50.
13. Regensteiner JG, Ware JE Jr, McCarthy WJ et al. Effect of cilostazol on treadmill walking, community-based walking ability and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50: 1939-46.
14. Katz MF, Farber HW, Dodds-Stitt Z, Cruikshank WW, Beer DJ. Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic and growth factor. J Leukoc Biol 1994; 55: 567-73.
15. Prevention of Artherosclerotic Complications With Ketanserin (PACK) Claudication Substudy Investigators. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy. Circulation 1989; 80: 1544-48.
16. Verstraete M. The PACK trial; morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications. Vasc Med 1996; 1: 135-40.
17. Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int Angiol 2002; 21: 20-27.
18. Adhoute G, Andreassian B, Boccalon H et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 1990; 16 (suppl 3): S75-S80.
19. Moody AP, al-Khaffaf HS, Lehert P, Harris PL, Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994; 23 (suppl 3): S44-S47.
20. Kieffer E, Bahnini A, Mouren X, Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 2001; 20: 58-65.
21. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angeiol (Paris) 2001; 50: 175-82.
22. Hiatt WR, Hirsch AT, Cooke JP, Olin JW, Brater DC, Creager MA. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vasc Med 2004; 9: 18-25.
23. Lindgarde F, Jelnes R, Bjorkman H et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989; 80: 1549-56.
24. Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP. A dose-effect of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 1996; 27: 788-93.
25. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34: 1618-24.
26. Dawson DL, DeMaioribus CA, Hagino RT et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999; 178: 141-46.
27. Fujita M, Mizuno K, Ho M et al. Sarpogrelate treatment reduces restenosis after coronary stenting. Am Heart J 2003; 145: e16.
28. Yamakawa J, Takahashi T, Itoh T et al. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Diabetes Care 2003; 26: 2477-78.